The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

Neurology

Volumn 63, Issue 6, 2004, Pages 1079-1080

  Morrow, S A ^a   Stoian, C A ^b   Dmitrovic, J ^b   Chan, S C ^b   Metz, Luanne M ^b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 4644357256     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000138572.82125.F5     Document Type: Article

References (10)

1. Beck RW, Cleary PA, Anderson MM Jr., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-588.
2. Barnes D, Hughes RAC, Morris RW, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906.
3. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769.
4. Metz LM, Harris CJ, Moore A, et al. MS patients choice of oral rather than IV steroid therapy results in savings to the health care system. International Journal of MS Care [serial online] 2000;2(2). Available at: http://mscare.com. Accessed November 25, 2003.
5. Metz LM, Sabuda D, Hilsden RJ, Enns R, Meddings JB. Gastric tolerance of high dose pulse oral prednisone in multiple sclerosis. Neurol 1999;53:2093-2096.
6. Stubbs SS. Corticosteroids and bioavailability. Transplant Proc 1975;7:11-19.
7. Antal EJ, Wright CE III, Gillespie WR, Albert KS. Influence of route of administration on the pharmacokinetics of methylprednisolone. J Pharmacokinet Biopharm 1983;11:561-576.
8. Tse FLS, Welling PG. Relative bioavailability of prednisone and prednisolone in man. J Pharm Pharmacol 1979;31:492-493.
9. Hayball PJ, Cosh DG, Ahern MJ, Schulz DW, Roberts-Thomson PJ. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992;42:85-88.
10. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-39.